Topotecan1 mg/ml

Topotecan is a topoisomerase I inhibitor anticancer (cytotoxic chemotherapy) agent used under the supervision of an oncologist. Its evidence-based indications are:

Established / FDA-approved indications

• Metastatic ovarian cancer — as a single agent, after disease has progressed on or after initial or subsequent chemotherapy.
• Small cell lung cancer (SCLC), platinum-sensitive disease — as a single agent, in patients who progressed at least 60 days after completing first-line chemotherapy.
• Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation — used in combination with cisplatin (combination therapy is required for this indication; Topotecan is not used alone for cervical cancer).

Off-label / investigational use

Topotecan has been studied off-label in other relapsed/refractory solid tumours and paediatric malignancies (e.g., neuroblastoma, rhabdomyosarcoma, Ewing sarcoma) in clinical trial settings; such use should only occur under specialist oncology protocols, as safety and efficacy for these uses are not formally established.

Topotecan is available as a sterile, single-dose, lyophilized powder for injection, formulated as topotecan hydrochloride equivalent to 4 mg of Topotecan free base per vial (also supplied in some markets as ready-to-use injectable concentrate). An oral capsule formulation of Topotecan (0.25 mg and 1 mg strengths) exists in some markets. Confirm the exact strength and formulation on the product label dispensed, as formulation and strength can vary by manufacturer.

Topotecan is a semisynthetic derivative of camptothecin and belongs to the topoisomerase I inhibitor class of cytotoxic anticancer agents. It is administered intravenously (and in some markets, orally) as part of chemotherapy regimens for specific relapsed or advanced solid tumours. Because of its narrow therapeutic index and significant risk of bone marrow suppression, Topotecan must be prescribed, prepared, and administered only by, or under the direct supervision of, a physician experienced in the use of cytotoxic chemotherapy, with regular laboratory monitoring.

Topotecan belongs to the topoisomerase I inhibitor class of antineoplastic (anticancer/cytotoxic chemotherapy) agents, a subclass of camptothecin derivatives.

Mechanism of action

Topotecan inhibits the enzyme topoisomerase I, which normally relieves torsional strain in DNA during replication by creating transient single-strand breaks and then resealing (religating) them. Topotecan binds to and stabilizes the topoisomerase I–DNA cleavable complex, preventing religation of these single-strand breaks. When the replication fork encounters this stabilized complex, it causes irreversible double-strand DNA damage, which is lethal to rapidly dividing cells, including tumour cells (and also to normal rapidly dividing cells such as bone marrow precursors, explaining its main toxicity).

Pharmacokinetics

After intravenous infusion, Topotecan undergoes pH-dependent, reversible hydrolysis between an active lactone form and an inactive hydroxy-acid form. It has a relatively short elimination half-life (approximately 2–3 hours), moderate plasma protein binding, and is cleared by a combination of renal excretion and non-renal (metabolic/biliary) pathways, with renal clearance representing a significant elimination route — hence the need for dose adjustment in renal impairment. No clinically significant pharmacokinetic differences have been observed in hepatic impairment.

Topotecan is a cytotoxic drug and must be handled and administered with standard precautions for hazardous chemotherapy agents (protective gloves/gown, safe handling and disposal procedures).

• Administer strictly by slow intravenous infusion over 30 minutes, as prescribed; do not administer by rapid IV push or bolus.
• Confirm CBC parameters meet required thresholds before every dose.
• Avoid extravasation; although tissue damage from extravasation is uncommon, if it occurs, stop the infusion immediately and manage per institutional extravasation protocol.
• Topotecan capsules (oral formulation, where available) are swallowed whole with water, not chewed, crushed, or opened.
• Do not mix Topotecan with other medicines in the same infusion line unless compatibility has been confirmed.

Only well-established, clinically significant interactions are listed:

• Other myelosuppressive chemotherapy or radiotherapy: concurrent or recent use increases the risk of additive bone marrow suppression; combination regimens require closer haematological monitoring and dose modification.
• Cisplatin: used deliberately in combination for cervical cancer; no clinically significant pharmacokinetic interaction is seen with this specific sequence/dosing, but the combination increases overall myelosuppression risk and requires the specific reduced Topotecan dose (0.75 mg/m²/day) described in Dosage.
• Granulocyte colony-stimulating factors (e.g., filgrastim, G-CSF): if used to manage neutropenia, do not start G-CSF until at least 24 hours after completing the last dose of Topotecan in a cycle, and do not start a new Topotecan cycle until at least 24 hours after the last G-CSF dose, as concurrent use can prolong or worsen neutropenia.
• P-glycoprotein inhibitors and other narrow-therapeutic-index drugs affecting drug transporters: may theoretically alter Topotecan exposure; use with caution and inform the treating oncologist of all concurrent medicines, including herbal/OTC products.

Topotecan commonly causes dose-related bone marrow suppression; the most frequent adverse effects seen in clinical trials include:

Very common

• Neutropenia (including severe/Grade 3–4 neutropenia in a majority of treated patients), anemia, and thrombocytopenia — see Precautions and Warnings for the boxed warning on myelosuppression.
• Nausea, vomiting, and diarrhoea.
• Fatigue, weakness (asthenia), and alopecia (hair loss).
• Fever, and febrile neutropenia in a substantial minority of patients.

Less common but clinically important

• Interstitial lung disease (rare, but can be fatal — see Precautions and Warnings).
• Elevated liver enzymes, mucositis, and hypersensitivity reactions.
• Extravasation-related local tissue reactions at the injection site.

Patients should report fever, unusual bleeding/bruising, severe fatigue, breathlessness, or signs of infection to their oncology team immediately.

Pregnancy: Topotecan can cause fetal harm based on its mechanism of action (DNA damage to rapidly dividing cells) and animal reproduction data, and is considered contraindicated in pregnancy in most clinical practice. Topotecan should not be used during pregnancy. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose; males with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. If pregnancy occurs during treatment, the patient should be advised of the potential risk to the fetus and referred promptly for specialist counselling.

Lactation: because of the potential for serious adverse reactions in a breastfed infant, breastfeeding should be discontinued during Topotecan treatment and for at least 1 week after the final dose. Consult the treating physician before resuming breastfeeding.

Boxed warning: severe bone marrow suppression

Topotecan can cause severe, sometimes life-threatening, bone marrow (myelosuppression), including neutropenia (with risk of febrile neutropenia and sepsis), thrombocytopenia (with risk of bleeding), and anemia. Topotecan should only be administered to patients with adequate baseline bone marrow reserve, and must be prescribed and monitored only by a physician/oncologist experienced in the use of cytotoxic chemotherapy.

• Obtain a baseline complete blood count (CBC) and repeat CBC monitoring frequently during each treatment cycle, and before every subsequent cycle.
• Do not start a new cycle unless neutrophil, platelet, and haemoglobin counts have recovered to acceptable levels (see Dosage).
• Dose reduction, cycle delay, or use of supportive growth factors may be required based on blood count nadirs — see Interaction section for G-CSF timing.

Interstitial lung disease (ILD)

Cases of ILD, some fatal, have been reported with Topotecan. Monitor for new or worsening cough, fever, or breathlessness, and evaluate promptly; discontinue Topotecan if ILD is confirmed.

Renal impairment

Dose reduction is required in moderate renal impairment (creatinine clearance 20–39 mL/min); see Dosage. Use in severe renal impairment (creatinine clearance below 20 mL/min) is not recommended due to insufficient safety data.

Extravasation and handling

Topotecan is a cytotoxic agent; follow institutional protocols for safe preparation, administration, spill management, and disposal. Mild extravasation reactions (redness, swelling) can occur.

General

Topotecan should be administered only in a facility equipped to manage chemotherapy-related complications, including febrile neutropenia and sepsis. See Contraindications and Pregnancy and Lactation for absolute restrictions.

Overdose with Topotecan would be expected to worsen dose-related toxicity, primarily severe bone marrow suppression (profound neutropenia, thrombocytopenia, anemia) and gastrointestinal mucosal toxicity. There is no specific antidote for Topotecan overdose.

If an overdose is suspected, seek immediate medical attention or contact emergency services/poison control right away. Management in a hospital setting involves close monitoring of blood counts and supportive care (e.g., transfusions, growth factors, antibiotics for infection) as clinically indicated; do not attempt home treatment.

Store refrigerated between 2°C and 8°C (36°F–46°F), in the original carton, protected from light, until ready for reconstitution/use. Keep out of reach of children. Follow the specific manufacturer's storage instructions on the pack, as formulations may vary. Reconstituted/diluted solutions have limited stability — see Reconstitution section — and any unused portion should be discarded appropriately as cytotoxic waste.

• Renal impairment: dose reduction required for creatinine clearance 20–39 mL/min; not recommended below 20 mL/min (see Dosage).
• Hepatic impairment: no dose adjustment established as necessary based on available data, but use with caution and close monitoring.
• Elderly patients: no overall differences in efficacy were observed compared with younger adults in clinical trials, but elderly patients, particularly those with reduced renal function, should be monitored closely for increased toxicity.
• Pregnancy and lactation: see Pregnancy and Lactation section — contraindicated in pregnancy; breastfeeding should be discontinued.
• Paediatric patients: see Pediatric Uses section.

Topotecan is typically continued for multiple 21-day cycles, as determined by the treating oncologist, until disease progression, unacceptable toxicity, or maximum benefit is achieved. The exact number of cycles is individualized based on tumour response (assessed periodically by imaging/clinical evaluation), blood count recovery between cycles, and overall tolerability. Treatment should not be continued or restarted without confirming adequate bone marrow recovery before each new cycle.

For the lyophilized powder-for-injection formulation of Topotecan (4 mg/vial): reconstitute using the diluent volume specified on the product label (commonly 4 mL of sterile Water for Injection) to yield a solution containing approximately 1 mg/mL of Topotecan. Gently swirl until fully dissolved; do not shake vigorously. The reconstituted solution is further diluted in 0.9% Sodium Chloride Injection or 5% Dextrose Injection to the required concentration for infusion. Use reconstituted/diluted solution promptly; if storage is unavoidable, follow the manufacturer's stated maximum storage time and temperature (typically up to 24 hours at room temperature, protected from light, for the diluted infusion). Discard any unused reconstituted solution appropriately as cytotoxic waste; do not use if particulate matter or discolouration is observed.

Topotecan is classified under: Antineoplastic agents → Topoisomerase inhibitors → Topoisomerase I inhibitors → Camptothecin derivatives.

Topotecan inhibits topoisomerase I, trapping the topoisomerase I–DNA cleavable complex and preventing resealing of single-strand DNA breaks made during replication. Collision of the replication fork with this stabilized complex produces irreversible double-strand DNA damage, triggering cell death in rapidly dividing cells, which underlies both its anticancer effect and its bone-marrow toxicity.

D

The safety and effectiveness of Topotecan in paediatric patients have not been formally established for its approved adult indications (ovarian cancer, SCLC, cervical cancer). Topotecan has been used off-label, under specialist paediatric oncology protocols, in certain relapsed or refractory paediatric solid tumours (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma), with dosing individualized by body surface area and close haematological monitoring, given the same bone marrow suppression risks described in Precautions and Warnings. Topotecan should only be given to a child under the direct care of a paediatric oncology specialist.